You just read:

Lenvatinib Delays Deterioration in Certain Domains of Quality of Life in Patients with Unresectable Hepatocellular Carcinoma as Compared to Sorafenib in Phase 3 REFLECT Study

News provided by

Eisai Inc.

Sep 10, 2017, 06:15 ET